- Chromocell Therapeutics, a Phase 1 biotech developing a non-addictive pain blocker using a sodium ion channel
- HQ North Brunswick, New Jersey
- https://chromocell.com/
Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions.
The company's lead compound is being prepared for a Phase 2a study for erythromelalgia patients with a genetic component.
The global market for erythromelalgia treatment is estimated to reach $3.5 billion by 2032, driving potential growth for Chromocell.
No comments:
Post a Comment